NASDAQ: APYXApyx Medical Corp Stock
$0.98+0.05 (+5.38%)
Updated Apr 17, 2025
APYX Price
$0.98
Fair Value Price
N/A
Market Cap
$36.85M
52 Week Low
$0.76
52 Week High
$1.99
P/E
-1.48x
P/B
2.59x
P/S
1.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$48.10M
Earnings
-$23.46M
Gross Margin
61%
Operating Margin
-35.97%
Profit Margin
-48.8%
Debt to Equity
3.55
Operating Cash Flow
-$18M
Beta
1.3
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
APYX Overview
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APYX's potential to beat the market
- APYX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
APYX
RankedUnranked of 102
RankedUnranked of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important APYX news, forecast changes, insider trades & much more!
APYX News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APYX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APYX is good value based on its book value relative to its share price (2.59x), compared to the US Medical Devices industry average (3.8x)
P/B vs Industry Valuation
APYX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APYX due diligence checks available for Premium users.
Valuation
APYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.48x
Industry
41.14x
Market
27.98x
APYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.59x
Industry
3.8x
APYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APYX's financial health
Profit margin
Revenue
$14.2M
Net Income
-$4.6M
Profit Margin
-32.5%
APYX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
APYX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$64.8M
Liabilities
$50.5M
Debt to equity
3.55
APYX's short-term assets ($56.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APYX's short-term assets ($56.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APYX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$245.0k
Financing
$6.8M
APYX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APYX vs Medical Device Stocks
Apyx Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.